Novavax Inc. (NASDAQ: NVAX) has been a high-profile stock in the biotech sector, especially after its COVID-19 vaccine gained global attention. However, as the vaccine
Novavax, Inc. (NASDAQ: NVAX) has experienced a significant surge in its stock performance, buoyed by the unveiling of its financial outcomes. In the latest market
The outbreak of Covid-19 ushered the world into utter chaos, followed by continuous fear. Pharma giants rushed to make a viable vaccine for the virus
The stock of Novavax Inc (NVAX) followed a bearish pattern in the after-market after releasing its financial outlook for Q4 and FY21. In the after-market,
Novavax, Inc. (NVAX) gained a further 9.56% at $238.10 premarket, at the last check on Monday. The stock has been gaining on the news of
Novavax, Inc. (NVAX) stock prices were up by a marginal 2.31% as of the market closing on June 11th, 2021, bringing the price per share
Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition
BlackBerry Limited (BB) stock soared 21.29% to $8.49 in the pre-market trading following the announcement of its multi-year, global agreement with Amazon Web Services, Inc.
Novavax Inc’s (NVAX) stock was up 1.73% to trade at $125.6 in the premarket session today, despite the recent news that the company has again
Moderna Inc (MRNA) was up 20.24%on Monday at $152.74. The biotechnology company has therefore applied for marketing authorizations for its coronavirus vaccine in the United
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.